FDA will make a decision by Oct. 31 as to whether or not Zomax can return to the market, according to an agency memo of a Sept. 7 meeting between FDA and J&J. McNeil withdrew the drug in March 1983 following reports of anaphylactic reactions. The company has sought to bring Zomax back with indications limited to long-term use in patients with intractable pain
You may also be interested in...
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. And London-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.